Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T18:22:25.476Z.
Calculation as of: 2026-10-06T18:22:25.476Z.
Quote observation: 2026-10-06T18:20:06.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4efcc2f75e7b9d1a3dd193370b83b229becf15f1f7fcdbde4bbae966de3ea950
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Olema Pharmaceuticals, Inc.
Market Cap
$697.03M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$698.54M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$697.15M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$714.71M
Operating Cash Flow Yield
46.16%
TTM Avg
23.51%
3Y Avg
20.54%
5Y Avg
18.34%
Market Cap
$683.73M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$671.61M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$716.46M
Operating Cash Flow Yield
N/A
TTM Avg
5.57%
3Y Avg
5.48%
5Y Avg
5.48%
Market Cap
$720.96M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | $697.03M | N/A | N/A | N/A | N/A |
| Wave Life Sciences Ltd. (WVE)vs › | $698.54M | N/A | N/A | N/A | N/A |
| Anteris Technologies Global Corp. (AVR)vs › | $697.15M | N/A | N/A | N/A | N/A |
| Verastem, Inc. (VSTM)vs › | $685.85M | N/A | N/A | N/A | N/A |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $714.71M | 46.16% | 23.51% | 20.54% | 18.34% |
| Solid Biosciences Inc. (SLDB)vs › | $683.73M | N/A | N/A | N/A | N/A |
| ArriVent BioPharma, Inc. (AVBP)vs › | $671.61M | N/A | N/A | N/A | N/A |
| Avalo Therapeutics, Inc. (AVTX)vs › | $716.46M | N/A | 5.57% | 5.48% | 5.48% |
| Faeth Therapeutics, Inc. (FTH)vs › | $720.96M | N/A | N/A | N/A | N/A |
| Cytek Biosciences, Inc. (CTKB)vs › | $718.03M | N/A | 4.26% | 2.63% | 1.85% |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
